← Back to Search

Cognitive Remediation

SCORES for Schizophrenia Risk (SCORES Trial)

N/A
Recruiting
Led By Barbara A Cornblatt, Ph.D.
Research Sponsored by Northwell Health
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be younger than 65 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up baseline, mid-treatment (5 weeks), post treatment (10 weeks)
Awards & highlights

SCORES Trial Summary

This trial intervention is designed to help those at risk for schizophrenia by targeting processing speed, which is directly related to social functioning. The exercises and group support in the intervention are meant to improve motivation and engagement in adolescents.

Who is the study for?
This trial is for adolescents showing early signs of psychosis, specifically those who have certain symptoms but haven't been diagnosed with a schizophrenia-spectrum disorder. Participants should be English speakers without significant neurological issues, intellectual disability (IQ<70), major head injury, or severe sensory impairments.Check my eligibility
What is being tested?
The SCORES program aims to improve processing speed and social functioning over 10 weeks through cognitive exercises and group support. It's designed for young people at risk of developing schizophrenia or other psychotic disorders and is delivered remotely.See study design
What are the potential side effects?
Since SCORES involves cognitive training and support groups rather than medication, typical drug side effects are not expected. However, participants may experience fatigue or stress from the exercises or emotional discomfort during group discussions.

SCORES Trial Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~baseline, mid-treatment (5 weeks), post treatment (10 weeks)
This trial's timeline: 3 weeks for screening, Varies for treatment, and baseline, mid-treatment (5 weeks), post treatment (10 weeks) for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Processing Speed domain score from the MATRICS Consensus Cognitive Battery (MCCB)
Secondary outcome measures
Global Functioning: Social (GF:Social) scale (Phase 2/R33 only)
SIPS/SOPS: Positive Symptoms (Phase 2/R33 only)

SCORES Trial Design

1Treatment groups
Experimental Treatment
Group I: Single Arm interventionExperimental Treatment1 Intervention
All participants will complete 40 hours of Cognitive Remediation with a mid-point assessment (20 hours/5 weeks) to determine the level of training needed to impact processing speed.

Find a Location

Who is running the clinical trial?

National Institute of Mental Health (NIMH)NIH
2,785 Previous Clinical Trials
2,689,726 Total Patients Enrolled
1 Trials studying Prodromal Symptoms
220 Patients Enrolled for Prodromal Symptoms
Northwell HealthLead Sponsor
459 Previous Clinical Trials
470,943 Total Patients Enrolled
Barbara A Cornblatt, Ph.D.Principal InvestigatorNorthwell Health

Media Library

SCORES (Cognitive Remediation) Clinical Trial Eligibility Overview. Trial Name: NCT05131035 — N/A
Prodromal Symptoms Research Study Groups: Single Arm intervention
Prodromal Symptoms Clinical Trial 2023: SCORES Highlights & Side Effects. Trial Name: NCT05131035 — N/A
SCORES (Cognitive Remediation) 2023 Treatment Timeline for Medical Study. Trial Name: NCT05131035 — N/A

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Are there any open enrollment opportunities for this research trial?

"As indicated on clinicaltrials.gov, this trial is still looking for volunteers to participate in the study as it was posted on October 28th 2021 and recently updated on November 24th 2021."

Answered by AI

Who is eligible to join this research project?

"This medical trial is open to 30 adolescents aged 14 and 20 that display signs of psychosis. Prospective enrollees must exhibit at least one moderate-to-severe attenuated positive symptom as identified on the Structured Interview for Psychosis Risk Syndromes, a score representing 0.5 SD below the mean on Animal Naming, Trails A or BACS: Symbol Coding from the MATRICS Consensus Cognitive Battery (MCCB)."

Answered by AI

To what extent is participation being solicited for this trial?

"Affirmative. Clinicaltrials.gov attests that this clinical trial, posted on October 28th 2021, is actively seeking enrolment at the current moment in time. 30 people are needed for this study from a single medical facility."

Answered by AI

Is the eligibility criteria for this research trial limited to individuals aged 18 and above?

"To qualify for this trial, the age of participants must lie between 14 and 20 years."

Answered by AI
Recent research and studies
clinicaltrials.govStudy
Targeting Processing Speed Deficits to Improve Social Functioning and Lower Psychosis Risk
2021. "Targeting Processing Speed Deficits to Improve Social Functioning and Lower Psychosis Risk". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT05131035.
~14 spots leftby May 2026
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top